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Abstract
Background: In advanced non-small-cell lung cancer (NSCLC), with the increasing number of active compounds available in
salvage settings, survival after progression to first-line chemotherapy seems to have improved. A literature survey was
conducted to examine whether survival post-progression (SPP) has improved over the years and to what degree SPP
correlates with overall survival (OS).
Methods and Findings: Median progression-free survival (MPFS) time and median survival time (MST) were extracted in
phase III trials of first-line chemotherapy for advanced NSCLC. SPP was pragmatically defined as the time interval of MST
minus MPFS. The relationship between MPFS and MST was modeled in a linear function. We used the coefficient of
determination (r
2) to assess the correlation between them. Seventy trials with 145 chemotherapy arms were identified.
Overall, median SPP was 4.7 months, and a steady improvement in SPP was observed over the 20 years (9.414-day increase
per year; p,0.001) in parallel to the increase in MST (11.253-day increase per year; p,0.001); MPFS improved little (1.863-
day increase per year). Overall, a stronger association was observed between MST and SPP (r
2=0.8917) than MST and MPFS
time (r
2=0.2563), suggesting SPP and MPFS could account for 89% and 25% of the variation in MST, respectively. The
association between MST and SPP became closer over the years (r
2=0.4428, 0.7242, and 0.9081 in 1988–1994, 1995–2001,
and 2002–2007, respectively).
Conclusions: SPP has become more closely associated with OS, potentially because of intensive post-study treatments. Even
in advanced NSCLC, a PFS advantage is unlikely to be associated with an OS advantage any longer due to this increasing
impact of SPP on OS, and that the prolongation of SPP might limit the original role of OS for assessing true efficacy derived
from early-line chemotherapy in future clinical trials.
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Introduction
Non-small-cell lung cancer (NSCLC) accounts for approxi-
mately 75% of all lung cancer cases [1]. The majority of patients
with NSCLC have inoperable locally advanced or metastatic
disease at the time of diagnosis. The standard treatment for
advanced NSCLC has been platinum-based chemotherapy [2–4],
which, unfortunately, produces a median survival time (MST) of
only approximately 1 year [5–7]. In contrast, during the last
decade, several effective chemotherapeutic agents have been
developed for advanced NSCLC and have been shown to yield
significant survival advantages ,even in salvage settings [8–13].
Given its objectivity and the benefits derived by patients, overall
survival (OS) has been historically considered the most important
therapeutic objective in advanced NSCLC, whereas progression-
free survival (PFS) captures tumor shrinkage, tumor stabilization,
and their duration, all of which are essential for evaluation of new
target agents [14]. Currently, however, with the increasing
number of the aforementioned factors, the effects of subsequent
therapies may have the potential to affect the PFS advantage of
early-line therapies on OS advantage.
To date, few studies have addressed whether survival after
progression to first-line chemotherapy (survival post-progression
[SPP]) has substantially improved over the years and to what
degree SPP correlates with OS. SPP was first reported in 2009
[15] with use of a simple device. That is, OS was partitioned into
two parts by expressing it as the sum of PFS and this ‘‘survival
postprogression’’ (SPP) [ie, OS=PFS+(OS2PFS)] [15]. Here, the
standard definition of ‘‘progression’’ included death from any
cause and so the progression event may be death.
Based on the backgrounds, we conducted a literature survey to
address these clinical questions using an abstracted database of
randomized phase III trials of systemic first-line chemotherapy for
advanced NSCLC.
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atMethods
Eligibility criteria, information sources and search for
trials
A literature search was conducted for trials reported between
January 1991 and November 2010. To avoid publication bias,
both published and unpublished trials were identified through a
computer-based search of both the PubMed database and
abstracts from the past 10 conferences of the American Society
of Clinical Oncology, European Society for Medical Oncology,
and International Association of Study on Lung Cancer. The
following search terms were used: ‘‘lung neoplasm,’’ ‘‘carcinoma,’’
‘‘non-small cell,’’ ‘‘chemotherapy,’’ and ‘‘randomized controlled
trial.’’ The search was also guided by a thorough examination of
reference lists from original and review articles, relevant books,
meeting abstracts, and the Physician Data Query registry of
clinical trials.
Study selection
Phase III trials were eligible if they evaluated first-line systemic
chemotherapy for advanced or metastatic NSCLC. Among
chemotherapeutic agents, new agents were defined previously as
those including docetaxel, paclitaxel, vinorelbine, gemcitabine,
and irinotecan, while old agents were defined as those that had
been developed before these new agents were introduced clinically
Table 1. Trial demographics in 70 trials.
No. of randomly assigned patients per trial
(median; range)
403 (126–1725)
Year of trial initiation (median; range) 2002 (1988–2007)
Publication type (full text/abstract form only) 55/15
Primary endpoint (OS/PFS) 47/23
Proportion of pts with ECOG PS of 0 and 1
(median; range)
96 (0–100)*
Abbreviations: OS = overall survival, PFS = progression-free survival, ECOG PS
= Eastern Cooperative Oncology Group performance status.
*indicating the median score of proportion of good ECOG-PS patients in each
eligible trial and its range.
doi:10.1371/journal.pone.0026646.t001
Figure 1. The PRISMA flow chart showing the progress of trials through the review.
doi:10.1371/journal.pone.0026646.g001
Table 2. Characteristics of 145 chemotherapy arms in the 70
trials.
No. of treatment arms
Platinum-based regimens 110* (75.9%)
2 cisplatin-based 63 (43.4%)
+ new agent{ 33 (22.8%)
+ new agent + molecular-targeted agent{# 13 (9.0%)
+ other 17 (11.7%)
2 carboplatin-based 53 (36.6%)
+ new agent{ 39 (26.9%)
+ new agent + molecular-targeted agent{# 12 (8.3%)
+ other 2 (1.4%)
2 oxaliplatin-based 1 (0.7%)
Non-platinum regimens 35 (24.1%)
2 monotherapy 18 (12.4%)
2 combination therapy 17 (11.7%)
*In seven arms, cisplatin or carboplatin was investigated.
{New agent was defined as those including docetaxel, paclitaxel, vinorelbine,
gemcitabine, and irinotecan (see Methods section).
#Molecular-targeted agent was defined as agents acting on known specific
molecular targets, such as tyrosine kinase inhibitors, neutralizing antibodies,
and antisense oligonucleotides (see Methods section).
doi:10.1371/journal.pone.0026646.t002
PFS, SPP, and OS in Lung Cancer
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to act on known specific molecular targets, such as tyrosine kinase
inhibitors (TKIs), neutralizing antibodies, anti-angiogenic agents,
matrix metalloproteinase inhibitors, and antisense oligonucleo-
tides, were defined as molecular-targeted agents [17]. Trials that
provided data for median PFS (MPFS) and MST in each report
were included. Trials that were designed to assess combined
modality treatments, including radiotherapy and surgery, were
excluded. Clinical trials of salvage chemotherapy (second-line or
later setting) were also ineligible.
Data collection process and data items
To avoid bias in the data abstraction process, two medical
oncologists (Y.F. and K.H.), one of whom (K.H.) is board-certified
in medical oncology, independently abstracted the data from the
trials and subsequently compared their results, as described
previously [18–25]. The following information was obtained from
each report: year of trial initiation, number of patients random-
ized, treatment regimens, publication type, and primary endpoint.
MPFS and MST were also extracted from each report. Here, SPP
was defined as the MST minus the MPFS for each trial arm, based
on previous reports [26,27].
All data were checked for internal consistency. Disagreements
were resolved by discussions among the investigators, although
their frequencies and patterns were not formally recorded.
Principal investigators of the trials were contacted to confirm or
update the published data.
Summary measures and synthesis of results
Data from the phase III trials were evaluated through linear
regression analysis, by assigning a weight equal to the sample size
to each trial. The strength of associations was defined a priori using
the commonly accepted criteria for the coefficient of determina-
tion (r
2); briefly, it gives the proportion of the variance of one
variable that is predictable from the other variable. It is a measure
that allows for the determination of how certain one can be in
making predictions from a certain model. The coefficient of
determination is such that 0#r
2#1, and a higher r
2 score indicates
a stronger association. Correlations were described graphically
through bubble plots in which each bubble represents a pair of
arms with size proportional to the sample size of each trial. To
examine possible differential associations between MST and
MPFS and between MST and SPP, the analysis was repeatedly
conducted after stratifying several clinical factors (Table 4).
Differential associations were then evaluated by entering multipli-
cative interaction terms between each factor.
All p values were from two-sided tests, and significance was set
at p,0.05. Statistical analyses were conducted using the STATA
software (ver. 10; StataCorp, College Station, TX, USA).
Results
Trial demographics
Of the 3388 trials screened, 70 phase III trials (Table 1 and File
S1) initiated between 1988 and 2007 involving 38,721 patients
with advanced NSCLC were identified as having data regarding
survival data (Fig. 1). Sixty-four, five, and one of the 70 trials had
two, three, and four treatment arms, respectively, while we
excluded two best supportive care only arms. Finally, in total, 145
chemotherapeutic treatment arms with 34,501 randomly allocated
patients were eligible for this study. Trial characteristics and
chemotherapeutic regimens investigated are listed in Tables 1 and
2, respectively.
Trend in survival times of patients enrolled into phase III
trials
This study focused on the trend in survival time of patients
during the study period. Median SPP in the whole arm was 4.7
months. As seen in Fig. 2A and 2B, a scattergram demonstrates
the progressive improvement in the MST of advanced NSCLC
patients enrolled into phase III trials over the years with a
0.3751-month (11.253-day) increase per year (p,0.0001; blue).
Indeed, SPP was prolonged with 9 months in more recent trials
that were initiated in 2006 or 2007. Additionally, slopes of the
fitted lines of SPP (0.3138-month [9.414-day] increase per year,
p,0.0001; green) and MST (blue) were nearly parallel despite a
small improvement in MPFS (0.0621-month [1.863-day] in-
crease per year; pink), indicating that the gain in MST may
be primarily attributable to the increase in SPP rather than in
MPFS.
Factors affecting SPP
Next, a multiple regression analysis for SPP was conducted to
clarify which clinical factors could affect SPP (Table 3). The year
of trial initiation was a significant factor (regression coefficient of
0.2776; p,0.001), indicating that SPP has steadily increased over
the years even after adjusting other covariates listed in Table 3.
Additionally, a longer SPP time was associated with several clinical
Figure 2. Time trends in survival data. A. Trend in survival times in advanced NSCLC patients enrolled into phase III trials. Median survival time
(0.3751-month [11.253-day] increase per year; p,0.001; blue), median progression-free survival time (0.0621-month [1.863-day] increase per year;
p=0.006; pink), survival post-progression (0.3138-month [9.414-day] increase per year; p,0.001; green). All analyses were weighted by trial size. Y-
axis indicates survival time of each endpoint (months). B. Absolute mean SPP value per year. X-axis and Y-axis indicate year of trial initiation and mean
SPP value (months) in each year, respectively.
doi:10.1371/journal.pone.0026646.g002
Table 3. Multiple regression analysis for survival
post-progression (SPP).
Covariates
Regression
coefficient p-value
Year of trial initiation 0.2776 ,0.001
Proportion of patients with performance
status of 0 to 1
0.0536 0.002
Platinum use (yes vs. no) 20.6326 0.299
No. of chemotherapeutic agents combined
(single vs. doublet) 2.1705 0.011
(triplet or quartet vs. doublet) 20.6014 0.200
Use of older agents (yes vs. no)" 1.7061 0.070
Use of molecular-targeted agents (yes vs. no)1 1.0555 0.025
"Older agents were defined as those that had been developed before newer
drugs (i.e., docetaxel, paclitaxel, vinorelbine, gemcitabine, irinotecan) were
introduced clinically (see Methods section).
1Defined as agents acting on known specific molecular targets, such as tyrosine
kinase inhibitors, neutralizing antibodies, matrix metalloproteinase inhibitors,
and antisense oligonucleotides (see Methods section).
doi:10.1371/journal.pone.0026646.t003
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(p=0.002) and first-line use of monotherapy (p=0.011) and
molecular-targeted agent (p=0.025).
Associations between MST and MPFS and between MST
and SPP
MST and MPFS, and MST and SPP were plotted among the
145 chemotherapeutic arms. Overall, MST and MPFS were
weakly associated (r
2=0.2563), suggesting that MPFS explained
only 25.6% of the overall variability in MST (Fig. 3A).
Interestingly, however, the regression analysis revealed that several
clinical situations strengthened the association, such as when first-
line, platinum-based chemotherapy was investigated (r
2=0.7354)
compared with the situation in which agents other than platinum
were investigated (r
2=0.0849; p for interaction ,0.001; Table 4).
In contrast, SPP was strongly associated with MST (r
2=0.8917),
meaning that it could account for as much as 89% of the variation
in MST (Fig. 3B).
How the year of trial initiation affected the associations between
MST and MPFS and between MST and SPP was also examined.
Figure 3. Overall survival, progression-free survival and survival post-progression. A. Associations between median survival time and
median progression-free survival time (r
2=0.2563). B. Associations between median survival time and survival post-progression (r
2=0.8917). All
analyses were weighted by trial size.
doi:10.1371/journal.pone.0026646.g003
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into three generations on the basis of the year of trial initiation.
Each period was considered as follows: the early period when old
cytotoxic agents and cisplatin were primarily investigated (1988–
1994), the mid period when new cytotoxic agents and carboplatin
were introduced in phase III trials (1995–2001), and the late
period when molecular-targeted agents were introduced in phase
III trials (2002–2007). Despite there being no significant p-values
for an interaction, the association between MST and MPFS
seemed stably weak or a little bit weaker with the passing of the
years, while SPP became more strongly correlated with MST with
time (Table 4).
Discussion
This study investigated whether SPP, defined here as MST
minus MPFS for each trial arm [26,27], has improved substan-
tially over the years and to what degree SPP correlates with OS.
We showed a steady improvement in SPP over the past 20 years
(9.414-day increase per year), in parallel with the increase in MST
(11.253-day increase per year), while MPFS improved less (1.863-
day increase per year). MST was strongly associated with SPP time
(r
2=0.8917), not with MPFS time (r
2=0.2563). The association
between MST and SPP became stronger over the observed period
(r
2=0.4428, 0.7242, and 0.9081 in 1988–1994, 1995–2001, and
2002–2007, respectively). Longer SPP time was also associated
with several clinical situations, including first-line use of molecular-
targeted agents.
Because almost all patients with advanced NSCLC will suffer
from progression of their disease, the ultimate goal of palliative
chemotherapy is prolongation of OS as well as improvement in
patients’ symptoms and quality of life. Thus, the use of OS to
assess the efficacy of chemotherapies for advanced NSCLC seems
justified. Recently, however, there has been a growing debate on
the use of OS as the primary endpoint in oncological clinical trials
[28]. This debate has been going on for several years, especially in
cases of colorectal cancer [29–30]. In advanced colorectal cancer,
OS has been considered an insensitive efficacy criterion because
potentially active subsequent therapies are not controlled in most
randomized trials; OS may be increased or decreased by such
therapies [31]. In this situation, it is naturally supposed that
crossover would dilute and skew the true OS difference; thus, no
or few observed OS differences would not always indicate a lack of
survival advantage of the new compound if it goes beyond certain
boundaries [15].
From another point of view, Broglio et al. stressed through their
simulation study, the importance of SPP in understanding
treatment effects for metastatic cancers [15]. In their study, when
the median SPP was small, there was usually a statistically
significant benefit in OS when there was a statistically significant
treatment benefit in PFS. In contrast, longer periods of SPP added
randomness, diluting the treatment effect and making statistical
significance in OS decreasingly likely. Looking back on advanced
NSCLC, recent observations suggest that the use of effective
salvage therapies extends SPP in advanced NSCLC [9–13].
Additionally, we indeed found a gain in SPP over the years in the
Table 4. Associations between median survival time and median progression-free survival or survival post-progression.
No. of treatment arms MST vs. MPFS MST vs. SPP
Factors r
2 p (interaction)* r
2 p (interaction)*
,Type of anti-cancer agent .
Platinum-based chemotherapy
yes 109 0.0849 0.8451
no 35 0.7354 ,0.001 0.9699 ,0.001
Use of old chemotherapeutic agents
yes 24 0.2095 0.4986
no 120 0.2706 0.172 0.8970 0.123
Use of molecular-targeted agents
yes 42 0.3012 0.9208
no 102 0.2075 0.045 0.8058 0.196
,Trial design/characteristics.
Primary endpoint (overall survival)
yes 95 0.2156 0.8652
no 43 0.3842 0.137 0.9038 0.175
Publication type (full text)
yes 115 0.2996 0.8956
no 29 0.1199 0.238 0.8827 0.211
Year of trial initiation1
1988,1994 20 0.3266 0.4428
1995,2001 51 0.4214 0.517 0.7242 0.215
2002,2007 71 0.2319 0.220 0.9081 0.227
Abbreviations: MST = median survival time, MPFS = median progression-free survival, SPP = survival post-progression.
1The trials, initiated between 1988 and 2007, were simply divided into 3 generations on the basis of the year of trial initiation.
*We entered multiplicative interaction terms between each factor to assess the differential associations compared with each of the first-row categories.
doi:10.1371/journal.pone.0026646.t004
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study could be applied to recent clinical trial settings in advanced
NSCLC.
This study had several limitations. All analyses were conducted
using abstracted data, but without individual patient data (IPD).
Trial-level data, as described here, are not necessarily linked to
individual-level data, so our data cannot always be used to predict
an individual’s chance of survival on the basis of MPFS or SPP
shown here. Further IPD analysis will be performed to confirm the
current observations [32]. Also, this type of study retrospectively
analyzes somewhat heterogeneous data, meaning that study results
seem speculative, not definitive. Another critical problem is that
the incremental gain in survival (PFS and MST), rather than
formal parameters, proportional or absolute risk of events, was
applied here because a limited number of trials have reported
hazard ratios and thus predictions based on hazard ratio would
not be representative and could be biased. SPP was also used, the
definition of which has not been fully validated, but has been used
in previous reports [25,26]. These pragmatic approaches seem
easy to understand for clinicians involved in NSCLC treatment,
but the results obtained here are rather hypothesis-generating, and
thus remain to be confirmed by other studies using more formal
parameters. Furthermore, information of post-study chemothera-
pies and supportive care in each trial could not be obtained; thus,
details of why SPP time was prolonged remain unknown. Finally,
publication bias is a significant threat to the validity of such
analysis because it is difficult to completely rule out this possibility.
Thus, trials that had not yet been published as well as those that
had already been published were collected. All of these issues
could have potentially biased the present findings, and the results
should be interpreted cautiously.
In conclusion, this study demonstrated that even in advanced
NSCLC, SPP, rather than PFS, has became more strongly
associated with OS over the years, potentially because of intensive
post-study treatments. Due to this increasing impact of SPP on
OS, even in advanced NSCLC, a PFS advantage seems hardly
associated with an OS advantage any longer. This indicates that
the prolongation of SPP might limit the classical role of OS for
assessing true efficacy derived from early-line chemotherapy in
future clinical trials.
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